Transforming the discovery of novel GPCR-targeted therapies
About Us
Tectonic is a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-Protein Coupled Receptors (GPCRs). Tectonic was co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School.
We have developed a proprietary technology platform called GEODe™ to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease, by addressing challenges that have limited the pace of innovation in this field.
Our focus is on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life.
President and CEO, Director
Senior Vice President, Antibody Engineering & Protein Sciences
Chief Financial Officer
Chief Financial Officer
Peter McNamara, Ph.D.
Chief Scientific Officer
Peter McNamara, Ph.D.
Chief Scientific Officer
Anthony Muslin, M.D.
Chief Development Officer
Chief Medical Officer
Marc Schwabish, Ph.D.
Timothy A. Springer, Ph.D.
Phillip Donenberg
Board Director, Audit Chairman, Taysha Gene Therapies Former Chief Financial Officer, AveXis
Our Science
GPCRs are receptor molecules found on the surface of cells that act as sensors for various extracellular stimuli to enable communication between cells and their environment. They regulate diverse aspects of human biology including blood pressure, glucose metabolism, transmission between neurons and immune surveillance. There are over 800 human genes encoding GPCRs, underscoring the extent to which nature has relied on this molecular system for physiological control, and more than 30% of all approved drugs address targets in this class.
While the vast majority of these are small molecules, biologics present advantage in certain situations. For instance, when targeting a single member of a highly related family of GPCRs, the selectivity profile achievable with an antibody may be preferable to that of a small molecule to optimize therapeutic efficacy and safety for the patient. Conversely, when multi-modal action is needed to achieve a desired physiological effect, proteins engineered for bispecific function allow for dual target engagement, unlike small molecules that are generally optimized for action on a single target. Our focus is on developing biologics to address GPCRs with the goal of capturing such opportunities.
Tectonic has the expertise and experience in the biochemistry and biophysics of GPCRs, to translate basic research in this field into novel therapies. Our GEODe™ platform has the potential to overcome the challenges encountered to date in GPCR biologic discovery campaigns, and enable the advancement of novel GPCR-targeting therapies.
Our Recent Clinical Presentations
Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients
May 17, 2025 |
Download Poster
International Society for Heart and Lung Transplantation (ISHLT) 2025
TX000045 (TX45), A Novel Fc-Relaxin-2 Fusion Protein: Bioengineering and Preclinical Development for the Treatment of Group 2 PH
Apr 27, 2025 |
Download Poster
The tolerability, safety, pharmacokinetics, and pharmacodynamics of TX000045, a long-acting Fc-relaxin fusion protein after single doses in healthy volunteers
Nov 16, 2024 |
Download Poster
Pipeline
Tectonic development programs include first-in-indication opportunities
Careers
Current Openings
Senior Research Associate/
Associate Scientist
Director, Clinical Scientist
Principle Scientist/Sr Principle Scientist: Biologics Developability and Bioanalytical Characterization
To apply please send your resume to jobs@tectonictx.com
At Tectonic we are motivated by a “speak-up culture” where divergent perspectives are shared openly, respectfully, and fearlessly. We understand that we can learn from both triumphs and setbacks and that breakthroughs are often the result of the most unexpected insights.
We believe a shared commitment to excellence and creativity is what makes meaningful scientific and medical advances possible. We work hard yet find time to laugh together as we drive toward achieving a common goal-improving human health. We collaborate because we recognize the urgent need for new therapies and that teams score more goals than individuals. We value diversity both in who we are and in how we think because the more perspectives we bring to a challenge, the more likely we are to succeed.
Tectonic – a place to grow and succeed together.
Contact Us
490 Arsenal Way, Suite 210
Watertown, MA 02472
info@tectonictx.com
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
